Google
SLP Stock Analysis — SIMULATIONS PLUS INC (Healthcare >> Health Information Services)
SLP FAQ
What is SLP's P/E ratio?
SIMULATIONS PLUS INC (SLP) currently trades at a P/E ratio of 42.13.
What is SLP's ROE?
SIMULATIONS PLUS INC reports a Return on Equity (ROE) of 5.83%.
What is SLP's dividend yield?
SIMULATIONS PLUS INC offers a dividend yield of 0.00%.
What is SLP's Quality Score?
Our AI rates SLP's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy SLP?
Our AI Timing Score for SLP is 87 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does SLP belong to?
SIMULATIONS PLUS INC is classified under the Healthcare >> Health Information Services sector on the NASDAQ exchange
SLP AI Analysis Summary
Our AI summary for SLP: SIMULATIONS PLUS INC (NASDAQ), Healthcare >> Health Information Services sector. The stock currently trades at a P/E of 42.13, ROE of 5.83%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 87/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 18.23
Price
-0.07
(-0.38%)
Day Change
|
|
|---|
SLP, the overall quality is not good ( Quality = 31) but the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Negative growth of ROE in the last year.
Acceleration of ROA growth rate is below our criteria.
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Quality Factors |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 69 |
| Magic Formula Rank by ROA |
436
|
| Magic Formula Rank by ROE |
436
|
| Magic Formula Rank by ROIC |
425
|
| Price | 18.23 |
| PBV / Sector |
2.66 / 6.33
|
| Earning Per Share | 0.40 |
| PE / Sector |
42.13 / 46.50
|
| PEG or PE/Growth / Sector |
-0.16 / -0.41
|
| Average 1M Daily Value |
8.63 M
|
| Average 1W Daily Value |
5.44 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
41% |
| Ability to Make Profit |
|
52% |
| Return to Investors |
|
41% |
| Registration Details |
| Analyze Date | 2026-08-01 08:00:29 |
| Symbol | SLP |
| Name | SIMULATIONS PLUS INC |
| Sector | Healthcare >> Health Information Services |
| Market | NASDAQ |
| Listed Shares | 20.22 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 370.11 / 4,079.00 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 800 Park Offices Drive, Research Triangle Park, NC, United States, 27709
Phone: 661 723 7723
Website: https://www.simulations-plus.com
Employees: 212
Description: Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through Software and Services segments. The company offers GastroPlus, which predicts absorption, biopharmaceutics, pharmacokinetics, and pharmacodynamics in humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, OBESITYsym, and Thales products. In addition, the company offers Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Further, it provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Additionally, the company offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Research Triangle Park, North Carolina.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Health Information Services
Click a bubble to view stock details · Bubble size represents market capitalization share
Top Related Stocks
Stocks in the Same Sector
Healthcare › Health Information ServicesAnalysed on the same criteria, ordered by market cap